Abstract
Background: Thyroid Cancer (TC) is an endocrine organ malignancy that has become more common in recent decades. Vernodalin (VN), a cytotoxic sesquiterpene, has been reported to exhibit anticancer properties against human breast and liver cancer cells. However, no study has explored the efficacy of VN with respect to its antiproliferative and apoptotic action on human Papillary Thyroid Cancer cells (PTC).
Objective: The study intended to examine the antitumor and antiproliferative effects of VN and the apoptosis mechanisms underlying its action on TPC-1 human PTC cells.
Methods: In this study, we examined the VN cell viability by MTT assay; performed ROS measurement by DCFH staining method, MMP identification by Rh-123 staining method, and apoptotic morphological assay by employing AO/EB and DAPI stain method, and further, p38 MAPK/ERK/JNK cell proliferation markers were determined by western blotting technique.
Results: The findings showed that VN could inhibit the growth of PTC cells by increasing intracellular ROS, damaging MMP, and stimulating apoptosis in a concentration-dependent manner. The study demonstrated how VN inhibited TPC-1 cell viability by causing ROS-induced cell death via the MAPK signaling pathway.
Conclusion: VN may serve as an agonist to impact apoptosis in PTC cells. In human PTC, VN could play an effective role in chemotherapy. More studies pertaining to animal tumor models are needed to prove its anti-cancer effectiveness in vivo.
Graphical Abstract
[http://dx.doi.org/10.1146/annurev-med-061512-105739] [PMID: 24274180]
[http://dx.doi.org/10.1016/j.pathol.2017.09.003] [PMID: 29132721]
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0960] [PMID: 19240234]
[http://dx.doi.org/10.1089/thy.2009.1603] [PMID: 20001721]
[http://dx.doi.org/10.1586/era.12.8] [PMID: 22369326]
[http://dx.doi.org/10.1210/jcem.86.4.7407] [PMID: 11297567]
[http://dx.doi.org/10.1097/00005537-200403000-00001] [PMID: 15091208]
[http://dx.doi.org/10.1530/ERC-18-0476] [PMID: 30615595]
[http://dx.doi.org/10.4414/smw.2012.13659] [PMID: 22903797]
[http://dx.doi.org/10.1016/S0040-4020(01)82575-8] [PMID: 6047519]
[http://dx.doi.org/10.1080/01635581.2018.1445769] [PMID: 29543494]
[http://dx.doi.org/10.1016/j.cellsig.2006.02.001] [PMID: 16531007]
[http://dx.doi.org/10.1016/j.freeradbiomed.2005.10.056] [PMID: 16540388]
[http://dx.doi.org/10.1016/j.phrs.2020.104772] [PMID: 32283222]
[http://dx.doi.org/10.3892/ol.2015.3371] [PMID: 26622558]
[http://dx.doi.org/10.3998/ark.5550190.0008.731]
[http://dx.doi.org/10.1016/j.bse.2013.08.018]
[http://dx.doi.org/10.1371/journal.pone.0056643]
[http://dx.doi.org/10.1186/s13046-015-0266-y] [PMID: 26643256]
[http://dx.doi.org/10.1155/2022/6268755] [PMID: 35222800]
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[http://dx.doi.org/10.1002/jbt.22586] [PMID: 32711406]
[http://dx.doi.org/ 10.1101/pdb.prot4493]
[http://dx.doi.org/10.1089/thy.1999.9.369] [PMID: 10319943]
[http://dx.doi.org/10.1186/1472-6882-13-166] [PMID: 23837445]
[http://dx.doi.org/10.1126/science.298.5600.1869] [PMID: 12471231]
[http://dx.doi.org/10.1007/s10620-017-4856-8] [PMID: 29197940]
[PMID: 21959807]
[http://dx.doi.org/10.1021/jo01264a035] [PMID: 5357533]
[http://dx.doi.org/10.1021/jo01264a035]
[http://dx.doi.org/10.2741/1798] [PMID: 16146732]
[http://dx.doi.org/10.1016/j.cub.2014.03.034] [PMID: 24845678]
[http://dx.doi.org/10.3390/ijms18071388] [PMID: 28661430]
[http://dx.doi.org/10.1016/j.bbcan.2007.07.001] [PMID: 17693025]
[http://dx.doi.org/10.1002/jbt.22587] [PMID: 32726518]
[http://dx.doi.org/10.1016/j.tcb.2008.01.006] [PMID: 18296052]
[http://dx.doi.org/10.1038/sj.neo.7900003] [PMID: 10935465]
[http://dx.doi.org/10.3109/10715761003667554] [PMID: 20370557]
[http://dx.doi.org/10.1089/jmf.2018.0008] [PMID: 29733262]
[http://dx.doi.org/10.1021/acs.jafc.8b07126] [PMID: 30688446]
[http://dx.doi.org/10.1038/sj.leu.2401043] [PMID: 9639410]